Thursday, Jul 30, 2026

"granules-india-limited"

Granules India Limited receives final approval from USFDA for its new drug

Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients aged six years and older, as well as for Moderate to Severe Binge Eating Disorder (BED) in adults

Latest News

Bengaluru hotels warn of Swiggy boycott from Aug 15

5 mins ago
US federal jury convicts Salman Rushdie’s attacker of terrorism

18 mins ago
Ranbir Kapoor-Yash starrer ‘Ramayana: Part 1’ trailer unveiled in five languages

48 mins ago
US launches retaliatory strikes on Iran following ‘attacks’ on American forces

57 mins ago
Elon Musk’s xAI challenges Minnesota’s first-in-nation AI nudification ban

8 hours ago
Trainee IPS officer threatens to leak private chats after victim marries another man

8 hours ago
Mumbai police trace Sweden VPN in Aamir Khan threat probe

9 hours ago
Over 30 civilians killed in PoK protest crackdown by Pakistani forces

9 hours ago